EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Panaxia Labs Israel's enterprise value is ₪50.30 Mil.
Panaxia Labs Israel's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₪16.22 Mil. Therefore, Panaxia Labs Israel's EV-to-Revenue for today is 3.10.
The historical rank and industry rank for Panaxia Labs Israel's EV-to-Revenue or its related term are showing as below:
XTAE:PNAX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.96 Med: 2.93 Max: 36.73
Current: 3.1
During the past 8 years, the highest EV-to-Revenue of Panaxia Labs Israel was 36.73. The lowest was 0.96. And the median was 2.93.
XTAE:PNAX's EV-to-Revenue is ranked worse than 61.33% of 1024
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs XTAE:PNAX: 3.10
The historical data trend for Panaxia Labs Israel's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Panaxia Labs Israel's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Panaxia Labs Israel's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panaxia Labs Israel's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panaxia Labs Israel's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Panaxia Labs Israel's EV-to-Revenue falls into.
Panaxia Labs Israel's current Enterprise Value is ₪50.30 Mil.
Panaxia Labs Israel's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪16.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panaxia Labs Israel (XTAE:PNAX) EV-to-Revenue Explanation
Panaxia Labs Israel's share price for today is ₪94.80.
Panaxia Labs Israel's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪108.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panaxia Labs Israel EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Panaxia Labs Israel's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Panaxia Labs Israel (XTAE:PNAX) Business Description
Panaxia Labs Israel Ltd is engaged in the manufacture and distribution of medical cannabis products. The firm offers a wide range of products comprising oral tablets, sublingual tablets, medical oils, concentrations, pastilles, suppositories, topical creams, pain relief creams, and pain relief patches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTAE:PNAX has been successfully added to your 